Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Innate Pharma    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
7.015(c) 7.1(c) 7.17(c) 7.02(c) 7.07(c) Last
162 873 234 259 280 367 128 266 212 484 Volume
-1.75% +1.21% +0.99% -2.09% +0.71% Change
More quotes
Financials (EUR)
Sales 2019 90,6 M
EBIT 2019 -14,1 M
Net income 2019 -9,95 M
Finance 2019 49,3 M
Yield 2019 -
Sales 2020 105 M
EBIT 2020 -21,0 M
Net income 2020 -5,98 M
Finance 2020 115 M
Yield 2020 -
P/E ratio 2019 -38,2x
P/E ratio 2020 -141x
EV / Sales2019 5,61x
EV / Sales2020 4,23x
Capitalization 558 M
More Financials
Company
Innate Pharma specializes in the research and development of immunological-based drugs for cancers and infectious diseases treatment. The drug candidates belong to a new therapeutic class and are monoclonal antibodies targeting mechanisms of regulation of a particular compartment in our immune... 
More about the company
Surperformance© ratings of Innate Pharma
Trading Rating : Investor Rating :
More Ratings
Latest news on INNATE PHARMA
01/31INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claim..
BU
01/29INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims A..
BU
01/29Rosen Law Firm Announces Investigation of Securities Claims Against Innate Ph..
BU
01/14INNATE PHARMA : SA - French regulatory agency agrees lacutamab TELLOMAK trial ca..
AQ
01/13French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitme..
GL
01/13INNATE PHARMA : French regulatory agency agrees lacutamab TELLOMAK trial can res..
GL
01/09Tesla vindicated, Apple enjoys success in China, Boeing’s troubles continue…
01/09INNATE PHARMA : Provides update from regulatory agencies on lacutamab tellomak t..
GL
01/09Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK ..
GL
01/03INNATE PHARMA : SA - The European Medicines Agency accepts the regulatory submis..
AQ
01/02The European Medicines Agency Accepts the Regulatory Submission for Lumoxiti ..
GL
01/02INNATE PHARMA : The European Medicines Agency accepts the regulatory submission ..
GL
2019INNATE PHARMA : provides update on lacutamab TELLOMAK trial
AQ
2019Innate Pharma Provides Update on Lacutamab TELLOMAK Trial
GL
2019INNATE PHARMA : Provides Update on Lacutamab Tellomak Trial
GL
More news
News in other languages on INNATE PHARMA
01/14EN DIRECT DES MARCHES : Renault, Total, Vivendi, Ipsen, Valneva, Amazon, Visa..
01/14STOCK MARKET PARIS : Chine et Etats-Unis enterrent la hache de guerre (pour l'in..
01/14BIOTECH TIME : Innate redémarre, Valneva engrange, Noxxon se finance
01/14INNATE PHARMA : reprise de recrutement autorisé pour Tellomak
01/13INNATE PHARMA : L'agence réglementaire française autorise la reprise du recrutem..
More news
Analyst Recommendations on INNATE PHARMA
More recommendations
Sector news : Bio Diagnostics & Testing
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Bio Diagnostics & Testing
Chart INNATE PHARMA
Duration : Period :
Innate Pharma Technical Analysis Chart | IPH | FR0010331421 | MarketScreener
Technical analysis trends INNATE PHARMA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 12,05  €
Last Close Price 7,07  €
Spread / Highest target 121%
Spread / Average Target 70,5%
Spread / Lowest Target 27,3%
EPS Revisions
Managers
NameTitle
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Hervé Brailly Chairman-Supervisory Board & Head-Human Resources
Laure-Hélène Mercier CFO & Member-Executive Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Pierre F. Dodion Chief Medical Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
INNATE PHARMA18.62%598
EXACT SCIENCES CORPORATION10.86%15 112
GUARDANT HEALTH, INC.11.88%8 209
GENSCRIPT BIOTECH CORPORATION-1.24%4 237
IOVANCE BIOTHERAPEUTICS, INC.-10.12%3 140
INVITAE CORPORATION47.68%2 299